Humana Inc. (HUM) Price Target Increased to $275.00 by Analysts at Bank of America Corporation

Humana Inc. (NYSE:HUM) had its price target raised by stock analysts at Bank of America Corporation from $270.00 to $275.00 in a research report issued to clients and investors on Friday, July 14th. The brokerage presently has a “buy” rating on the insurance provider’s stock. Bank of America Corporation’s price target points to a potential upside of 11.82% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Cowen and Company restated an “outperform” rating and set a $230.00 target price on shares of Humana in a research report on Tuesday, April 25th. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $257.00 target price for the company in a research report on Thursday, May 25th. Leerink Swann boosted their target price on Humana from $250.00 to $265.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 30th. BidaskClub cut Humana from a “buy” rating to a “hold” rating in a research note on Tuesday, June 13th. Finally, UBS AG reaffirmed a “neutral” rating and set a $237.00 price objective (up from $205.00) on shares of Humana in a research note on Wednesday, June 28th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $241.65.

Shares of Humana (NYSE:HUM) traded down 1.17% on Friday, reaching $245.93. The company had a trading volume of 1,557,990 shares. The company has a 50-day moving average price of $236.19 and a 200-day moving average price of $220.68. The firm has a market cap of $35.54 billion, a P/E ratio of 20.23 and a beta of 0.91. Humana has a one year low of $163.50 and a one year high of $251.79.

Humana (NYSE:HUM) last released its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, topping analysts’ consensus estimates of $3.08 by $0.41. The company had revenue of $13.53 billion during the quarter, compared to the consensus estimate of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter in the previous year, the company posted $2.30 earnings per share. On average, analysts expect that Humana will post $11.40 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was reported by [[site]] and is the property of of [[site]]. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at [[permalink]].

In related news, VP Heidi S. Margulis sold 1,500 shares of the company’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $231.96, for a total transaction of $347,940.00. Following the sale, the vice president now owns 8,150 shares in the company, valued at $1,890,474. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Brian P. Leclaire sold 4,971 shares of the company’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total value of $1,193,040.00. Following the sale, the senior vice president now owns 14,258 shares in the company, valued at approximately $3,421,920. The disclosure for this sale can be found here. Insiders own 0.80% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in HUM. Guardian Life Insurance Co. of America raised its stake in Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares during the last quarter. Independent Portfolio Consultants Inc. raised its stake in Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock valued at $125,000 after buying an additional 94 shares during the last quarter. Point72 Asia Hong Kong Ltd bought a new stake in Humana during the first quarter valued at about $128,000. Westbourne Investment Advisors Inc. bought a new stake in Humana during the second quarter valued at about $205,000. Finally, Hengehold Capital Management LLC bought a new stake in Humana during the second quarter valued at about $209,000. Institutional investors and hedge funds own 99.62% of the company’s stock.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.